Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RUNX3 antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Boston Children's Hospital
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RUNX3 antisense oligonucleotide is an experimental antisense oligonucleotide (ASO) designed to target and inhibit the expression of Runt-related transcription factor 3 (RUNX3). Developed by researchers at Boston Children's Hospital, this therapeutic agent is being investigated for its potential to treat chronic inflammatory joint diseases, such as rheumatoid arthritis. RUNX3 is a key transcription factor involved in the convergent differentiation pathway of tissue-resident memory T cells (TRM) in the synovium. By blocking RUNX3 expression, the ASO prevents the formation of synovial TRM from circulating effector memory T cells (TEM) and central memory T cells (TCM), thereby reducing joint inflammation and preventing arthritis flares.
- Other names
- Runx3 ASORunx-3 ASORunx 3 ASORunx3 antisense oligonucleotideRunx-3 antisense oligonucleotideRunx 3 antisense oligonucleotideantisense oligonucleotide against Runx3antisense oligonucleotides against RUNX3
02
Targets
RUNX3 (Runt-related transcription factor 3)
Beyond the preview
Go deeper on RUNX3 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RUNX3 antisense oligonucleotide.